Trained as an emergency care physician and later graduated with the MBA from INSEAD. He held several managerial positions in the pharmaceutical industry in Europe, the USA and Canada. During his tenures, he led three teams which developed, filed and registered three products. In the early 2000, he founded and developed three start-up companies in the health care field. Two were sold to major US pharma and one to an LBO investment fund. In 2009, backed up by private investors, he acquired Mutabilis’ equity. He reorganized the company and focused the R&D projects on new antibiotics and new beta-lactamase inhibitors active against Gram-negative bacteria.
Director of Chemistry
Sophie has more than 20 years of experience in medicinal chemistry, from Cephalon in 1997 to Novexel in 2007 where she discovered improved Avibactam derivatives. Further to Novexel’s acquisition by Astra-Zeneca in 2010, Sophie joined Mutabilis where she now heads the Medicinal Chemistry team. She co-authored 8 publications and 18 patents.
Francois has a 20-year experience in drug discovery. After 6 years with Pfizer as leader of several drug discovery projects in allergy and respiratory diseases, François joined Mutabilis in 2004 to explore the novel concept of antivirulence drugs besides the classical antibacterial approach. He also contributed to the development of a new class of antibacterials, the FabI inhibitors and a new class of antiretrovirals, the allosteric inhibitors of HIV integrase (ALLINIs). François is co-author of 24 articles and co-inventor of 11 patents.
Wandrille RACT MADOUX
Graduated in 2000 from HEC, the leading French Business School, he started his career in M&A at JP Morgan and then as an entrepreneur. After 2 years at SG Capital Europe a PE fund, in 2005, he joined WCP, a mid-cap LBO fund at its creation. In 2012, he joined POI, the shareholder of Mutabilis, as CBO/CFO. He is also in charge of Mutabilis Strategy, Finance and business development.